Cilostazol vs. Aspirin in Acute Non-cardioembolic Stroke With Cerebral mIcrobleeds

Launched by ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL · Jul 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two medications, cilostazol and aspirin, to see which one is better for preventing future strokes in patients who have recently had a specific type of stroke called acute non-cardioembolic ischemic stroke and also have small areas of bleeding in the brain known as cerebral microbleeds. The goal is to find out if cilostazol is as effective and safe as aspirin in helping these patients avoid another stroke.

To participate in this study, individuals must have had an ischemic stroke within the last month and must have confirmed cerebral microbleeds. Participants will take either cilostazol or aspirin daily and will be monitored over several years, with check-ins at the hospital and follow-ups at 3 months, 6 months, and annually for up to 4 years. The main focus will be on whether they have another stroke and any serious side effects, such as significant bleeding. This trial is currently recruiting participants of all genders, so if you or a loved one meet the criteria, you might consider joining to help advance our understanding of stroke prevention.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Acute ischemic stroke (within 1 month of onset)
• • Non-cardioembolic stroke
• • Presence of cerebral microbleeds (CMBs) confirmed by susceptibility-weighted imaging (SWI)
• Exclusion Criteria:
• • Previous diagnosis of cerebral amyloid angiopathy (CAA) according to the Boston 2.0 diagnostic criteria
• • History of intracerebral hemorrhage highly suspected to be caused by CAA-related lobar hemorrhage
• • Severe adverse reactions (such as active bleeding, severe allergies, etc.) to aspirin or cilostazol in the past, leading to non-compliance with medication
• • Requirement for combined anticoagulant therapy
• • Requirement for long-term dual antiplatelet therapy (\>1 month)